Bartronics India Ltd. — Capital/Financing Update 2026

Mar 11, 2026

Date: 11[th] March, 2026

To, BSE Limited, Listing Department, P.J. Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 532694	To, National Stock exchange of India Limited, Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: ASMS

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to our earlier intimation dated February 27, 2026 and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“ Listing Regulations ”) we hereby inform you that the Company has made an equity investment in Huwel Lifesciences Private Limited (“Huwel”) amounting to INR 7,50,00,400/- (Indian Rupees Seven Crore Fifty Lakha and Four Hundred Only).

Pursuant to the said investment, the Company has acquired 9,665 equity shares of Huwel at a price of INR 7760/- per share, including a premium of INR 7750/- per share, representing 2.11% of the paid-up equity share capital of Huwel.

The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as per ‘ Annexure A’

This is for your information and Records.

Thanking You,

Yours Faithfully, For Avio Smart Market Stack limited (Formerly Known as Bartronics India Limited) DIKSHA Digitally signed by DIKSHA OMER OMER Date: 2026.03.11 15:09:53 +05'30' Diksha Omer Company Secretary

Annexure – A

Particulars	Details
Name of the target entity	M/s Huwel Lifesciences Private Limited(“Huwel”)
Whether the acquisition would fall within related party transactions and whether the promoter/promoter group has any interest inthe entity being acquired	The acquisition doesnotfall within the ambit of related party transactions. The promoter/promoter group/group companies haveno interestin the target entity.
Industry to which the entity being acquired belongs	Lifescience and Health
Objects and effects of acquisition	To derive operational and financial synergies.
brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
indicative time period for completion of the acquisition	The first tranche has been completed, and the remaining tranches will be completed in accordance with the terms and conditions specified in the Shareholders’ Agreement.
Whether the acquisition is at arm’s length	Yes, the acquisition is to be at arm’s length basis.
Details of consideration	INR 7,50,00,400/- (Indian Rupees Seven Crore Fifty Lakha and Four Hundred Only)
Mode of consideration	Cash
Percentage of shareholding/control acquired	2.11% of the paid-up equity share capital of Huwel
Cost of acquisition or the price at which shares are acquired	The Company acquired 9,665 equity shares at a price of INR 7760/- per share, including a premium of INR 7750/- per share
brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	Date of incorporation:Huwel Lifesciences Private Limited, (CIN: U33111TG2015PTC097596) is a Private company incorporated on 10/02/2015. Brief background: The Target Entity is engaged in the business of development, manufacturing, and supply of molecular diagnostic kits, medical devices, and in-vitro diagnostic solutions. And serves hospitals, laboratories, and research institutions by providing products for disease detection and healthcare testing. Turnover: 2022-23 - 12.11 Cr. 2023-24 - 4.94 Cr. 2024-25 - 15.74 Cr. Country:Patancheru,Telangana, India